Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
Immobilized Anti-NKG2A Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus NKG2A&CD94, Fc,Avitag (Cat. No. NC4-C82F7) with a linear range of 0.1-16 ng/mL (QC tested).
The purity of Rat NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (Cat. No. NC4-R5258) is more than 90% and the molecular weight of this protein is around 145-160 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Monalizumab | NN-8765; IPH-2201; NNC-0141-0000-0100 | Phase 3 Clinical | Innate Pharma, Novo Nordisk A/S | Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Mouth Neoplasms; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Inflammation; Head and Neck Neoplasms; Genital Neoplasms, Female; Breast Neoplasms; Arthritis, Rheumatoid; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Hematologic Neoplasms | Details |
BMS-986315 | BMS-986315 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
S-095029 | S-095029 | Phase 2 Clinical | Institut De Recherches Internationales Servier | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung | Details |
BRY-805 | BRY805; BRY-805 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
HY000102 | HY-0102; HY-000102 | Phase 1 Clinical | Shanghai HyaMab Biotech Co Ltd | Solid tumours | Details |
Monalizumab | NN-8765; IPH-2201; NNC-0141-0000-0100 | Phase 3 Clinical | Innate Pharma, Novo Nordisk A/S | Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Mouth Neoplasms; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Inflammation; Head and Neck Neoplasms; Genital Neoplasms, Female; Breast Neoplasms; Arthritis, Rheumatoid; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Hematologic Neoplasms | Details |
BMS-986315 | BMS-986315 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
S-095029 | S-095029 | Phase 2 Clinical | Institut De Recherches Internationales Servier | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung | Details |
BRY-805 | BRY805; BRY-805 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
HY000102 | HY-0102; HY-000102 | Phase 1 Clinical | Shanghai HyaMab Biotech Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.